Nuvectis Pharma, Inc.

Nuvectis Pharma to present at Maxim Growth Summ...
Pluang · 09 Oct 2026
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
GlobeNewswire · 09 Oct 2026
Nuvectis’ NXP200 receives breakthrough therapy status in China By Investing.com
Investing.com India · 24 Sep 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
GlobeNewswire · 24 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.